Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

July 2024

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial

Lancet Rheumatol 2024:S2665-9913(24)00099-7 DOI 10.1016/S2665-9913(24)00099-7 Epub ahead of print

Worth C,

Chan A,

Cook JA,

Corn TH,

Teh J,

Machado PM,

Taylor PC,

Bowness P

Worth, et al. found that namilumab did not show efficacy compared with placebo in patients with active axSpA, but the treatment was generally well tolerated. An unusually high proportion of ASAS20 responders at Week 12 were observed in the placebo group, which had a small sample size compared to the namilumab arm.

Keywords:

February 2024

Abatacept in Individuals at High Risk of Rheumatoid Arthritis (APIPPRA): A Randomised, Double-blind, Multicentre, Parallel, Placebo-controlled, Phase 2b Clinical Trial

Lancet doi.org/10.1016/S0140-6736(23)02649-1

Cope A,

Jasenecova M,

Vasconcelos J,

Filer A,

Raza K,

Pratt A,

Emery P,

Ho P,

Buch M,

Toes R,

Kelly J,

on behalf of the APIPPRA study investigators

Therapeutic intervention during the at-risk phase of RA with abatacept is feasible, with acceptable safety profiles. However, the efficacy of intermittent administration at multiple intervals remains to be assessed.